Specificity in the action of hypolipidemic drugs: increase of peroxisomal β-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat

Paul B. Lazarow,¹ Helen Shio, and Marie Anne Leroy-Houyet
The Rockefeller University, New York, NY 10021

Abstract Hypolipidemic drugs increased 3- to 4-fold the activity of the peroxisomal β-oxidation system in rat liver, with modest or no effects on catalase activity, liver weight, or peroxisome abundance. This specificity of action was observed in two experimental models: 1) bezafibrate treatment of male rats (25 mg/kg body wt., p.o.) and 2) clofibrate treatment of female rats (5 g/kg chow). Bezafibrate had no effect on the liver content of protein, catalase, or cytochrome oxidase, and little or no effect on mitochondrial β-oxidation. The results indicate that the hypotriglyceridemic mechanism of action of these drugs involves an induction of the peroxisomal β-oxidation system, but this mechanism does not obligatorily include gross hepatomegaly or other alterations of peroxisomes that are often caused by hypolipidemic compounds. This dissociation of specific biochemical changes from other effects demonstrates a precise regulation of organelle biogenesis. Peroxisomes synthesized under the influence of bezafibrate or clofibrate have a different enzymatic composition than do normal peroxisomes. These results have several implications. 1) Side effects of clofibrate that are of current clinical concern may be unrelated to its lipid-lowering effects. 2) Measurement of peroxisomal β-oxidation should be a sensitive and specific tool for screening for new hypotriglyceridemic compounds. 3) Peroxisome proliferation or lack thereof is not central to efficacy. 4) Other new drugs may be discovered that are highly discriminating in elevating specific enzymes of fatty acid catabolism while causing even less or no hepatomegaly and other side effects.—Lazarow, P. B., H. Shio, and M. A. Leroy-Houyet. Specificity in the action of hypolipidemic drugs: increase of peroxisomal β-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat. J. Lipid Res. 1982. 23: 317–326.

Supplementary key words mitochondria • bezafibrate • clofibrate • serum lipids • hepatic fatty acid oxidation • cell fractionation • morphometry

There is considerable interest in finding new drugs capable of specifically and safely lowering serum lipid levels. In evaluating new compounds, it would be helpful to know as much as possible about the mechanism of action of the existing drugs.

There are two separate systems for the β-oxidation of fatty acids in rat liver: the familiar mitochondrial system, and the peroxisomal system that we have described (1, 2). The peroxisomal system has also been detected in human liver (3). The activity of the peroxisomal β-oxidation system in male rats is increased one order of magnitude by the hypolipidemic drugs, clofibrate,2 tribenic acid,3 and Wy-14,6434 (1, 4), leading us to infer that increased peroxisomal β-oxidation plays an important role in the hypotriglyceridemic mechanism of action of these compounds (4, 5).

The three drugs mentioned above, as well as many analogous of clofibrate, also cause proliferation of hepatic peroxisomes, an increase in the activity of catalase (a major peroxisomal enzyme (6)), and an increase in liver weight (7–16). These latter effects, which are not necessarily desirable, are generally assumed to be obligatory properties of this class of hypolipidemic drugs. In addition, the possibility has been raised that peroxisome proliferators as a class may be carcinogenic (17, 18).

However, these latter effects are not observed under all conditions. In particular, clofibrate reduces serum lipid levels in both male and female rats, but did not affect peroxisome frequency or catalase activity in females (9, 10). In comparative studies, clofibrate caused peroxisome proliferation in dogs and hamsters, but not in squirrel monkeys and guinea pigs, at the dose tested (9). This raises some doubt concerning our conclusion that the mechanism of action of hypotriglyceridemic drugs involves an effect on peroxisomes.

1 To whom reprint requests should be addressed.
2 2-(p-Chlorophenox)-2-methylpropionic acid ethyl ester.
3 2-Chloro-5-(3,5-dimethylpyrrolidinofenyl) benzoic acid.
4 (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid.
5 Little information is available concerning the effect of hypolipidemic drugs on the abundance of peroxisomes in human liver. One patient treated with clofibrate had a lower mitochondria/peroxisomes ratio than three controls (15). This was interpreted as most likely being due to an increase in peroxisomes. Several female patients treated with Su-13437 did not show any notable change in the abundance of their hepatic peroxisomes (46).
It is entirely possible, however, that the peroxisomal \( \beta \)-oxidation enzymes could be induced without any effect on other peroxisomal enzymes or on the number of peroxisomes or on liver weight. Such induction would further support the proposed mechanism of action and would have important implications for the evaluation of new hypolipidemic drugs.

In order to test this possibility, we have investigated the effect of clofibrate on female rats. In addition, we have tested the effects of bezafibrate, a clofibrate analog that is active at lower doses (19), and which has recently been introduced into clinical use in West Germany. A dose and protocol (25 mg/kg p.o. to male rats) was selected which has previously been shown to produce 63% of the maximal hypotriglyceridemic effect (19). In these two experiments, we found large elevations of the peroxisomal \( \beta \)-oxidation system, with modest or sometimes no effects on other peroxisome parameters measured and on liver weight.

**METHODS**

**Drug treatments**

Three female Fisher F-344 rats (ca. 190 g) were fed ad lib. ground Purina lab chow containing 5 g of clofibrate per kg chow for 1 week. Three control rats received normal ground chow. Water was provided ad lib.

Six male Fisher F-344 rats (ca. 200 g) received 25 mg/kg body wt bezafibrate once daily at 11 AM by stomach tube as a 2.5 mg/ml suspension in 1% methylcellulose. Five control rats received methylcellulose only (10 ml/kg body wt). Treatment was for one week. The rats received pelleted Purina chow and water ad lib.

**Preparation of homogenates**

Rats were fasted overnight and then decapitated. Individual liver homogenates were prepared in 0.25 M sucrose/0.1% ethanol (1), each at a dilution of 1 g liver per 5 ml homogenate. In the bezafibrate experiment, the rats were anesthetized with ether prior to killing, and 1 ml of blood was withdrawn from the inferior vena cava for determination of plasma triglycerides and cholesterol.

**Cell fractionation**

Equal amounts (5–8 ml) of the homogenates within each experimental group were pooled. From each pool a postnuclear supernatant was prepared, which was then fractionated by the one-step gradient centrifugation method of Lazarow and de Duve (20) in order to separate the mitochondria, peroxisomes, microsomes, and cell sap. The organelles' locations in the gradient were determined by assaying their characteristic marker enzymes (21).

**Assays**

Enzyme assays were carried out on each homogenate and on all the various subcellular fractions that were prepared. Palmitoyl-CoA oxidation was measured by several methods. Palmitoyl-CoA-dependent reduction of NAD was assayed as described previously (1) in the presence of 1 mM KCN to prevent reoxidation of the NADH formed. Oxidation of [1-\( ^{14} \)C]palmitoyl-CoA (2 Ci/mol) was determined under similar conditions except that KCN was omitted (4). Under the conditions of these assays (which included Triton X-100), the mitochondrial \( \beta \)-oxidation system was not very active. In the bezafibrate experiment, we also measured the oxidation of [U-\( ^{14} \)C]palmitoyl-CoA under conditions where both mitochondria and peroxisomes were active (1 mM carnitine, 0.25 M sucrose, no Triton X-100) (22).

Catalase, cytochrome oxidase, and protein were determined according to Leighton et al. (23). Plasma cholesterol and triglycerides were measured according to Block, Jarrett and Levine (24) and Kessler and Lederer (25), respectively, using the Auto Analyzer II (Technicon Instrument Corp., Tarrytown, NY) in the laboratory of Dr. E. H. Ahrens, Jr. These automated procedures are standardized by the Center for Disease Control.

**Morphology**

Small pieces of liver were prepared for routine electron microscopic examination. The cytochemical reaction for catalase (26) was carried out as described previously (1) on additional liver samples. One-\( \mu \)m Epon sections were photographed under the light microscope; silver sections were photographed under the electron microscope.

**Morphometry**

Electron micrographs were photographed at random (27) using one or two blocks (one section/block) from each of three rats from each experimental group. The final magnifications were approximately 30,000; the exact magnifications were determined using a grating replica (E. F. Fullam, Inc., Schenectady, NY).

The peroxisome population was characterized by means of the size distribution analysis of Wicksell (28), using a Quantimet 720 (Cambridge Instruments, Cambridge, England) connected to a PDP 11/10 minicomputer, as described by Baudhuin et al. (29). Additional estimations of organelle volume and number were made using multipurpose test systems as described by Weibel, Kistler, and Scherle (27).
Computations

Statistical comparisons were made by means of the Student’s t-test. Cell fractionation data were computed and plotted according to Leighton et al. (23).

Materials

Fisher F-344 rats were purchased from Microbiological Associates (Bethesda, MD); reagents were from Sigma (St. Louis, MO). Clofibrate and bezafibrate were supplied by Ayerst Laboratories (New York, NY) and by Boehringer Mannheim (Mannheim, Federal Republic of Germany), respectively. [1-14C]- and [U-14C]-palmitoyl-CoA were obtained from New England Nuclear (Boston, MA).

RESULTS

Effects of clofibrate on female rats

Biochemical results. Liver homogenates prepared from clofibrate-treated female rats were about 3 times more active in oxidizing palmitoyl-CoA than were control homogenates, under conditions that mainly measured the peroxisomal β-oxidation system (Fig. 1).

Similar results were obtained by means of two independent assay procedures: NAD reduction (Fig. 1A) and [1-14C]palmitoyl-CoA oxidation (Fig. 1B). The mean activity of the controls of 0.8 μmol NAD reduced per min per g liver was similar to that observed previously for male rats (1, 4).

Clofibrate had no significant effect (Fig. 2) on the activity of catalase, the principal peroxisomal enzyme, in confirmation of the results of Svoboda, Azarnoff, and Reddy (10). This differs from the 30–140% increase observed in males (1, 4, 7, 9, 10). Clofibrate also had no effect on cytochrome oxidase activity or on protein concentration (Fig. 2).

Liver weight increased 22% in the drug-treated females (P < 0.05). Multiplying the rate of palmitoyl-CoA oxidation per g of liver by this increase in liver weight shows that the total liver capacity for palmitoyl-CoA oxidation is 3.6–4.0 times greater in the rats that received clofibrate than in the controls.

Morphological results. Light microscopic examination (Fig. 3A) indicated that clofibrate does not cause the striking changes in peroxisomes that are seen in male rats at this dose (Fig. 3B). This is consistent with previous reports by Svoboda et al. (9, 10). However, morphometric analysis revealed that the number and the total volume of peroxisomes did approximately double (not illustrated). This increase in volume is modest in comparison to the 3- to 10-fold increases observed for male rats (8, 9, 16, 30, 31 and confirmed by us for Fig. 3B).

Cell fractionation results. Postnuclear supernatants prepared from pooled homogenates were fractionated by sucrose gradient centrifugation (20). As illustrated in Fig. 4, the distributions of protein, catalase, and cytochrome oxidase from the clofibrate-treated rat livers were similar to those of the controls. Protein and these enzymes were not affected by the drug treatment.

From previous work (20) we know that the soluble cell sap proteins largely remain in the top two fractions where the postnuclear supernatant was layered (at the left in Fig. 4). The next two or three fractions were found to consist largely of microsomal protein. These components were not investigated in the present experiments.
absolute activities were about 3 times greater than in the 
clofibrate-treated rats was also peroxisomal, but the 
effects of bezafibrate on male rats 
shape of the palmitoyl-CoA oxidation distributions from 
the drug-treated rats. This demonstrates that the increased activities 
measured in the homogenates were due to the peroxi-
somal P-oxidation system. The 
mitochondria, detected by their content of cyto-
chrome oxidase, were in the center of the gradient at 
density 1.19 g/ml, coincident with a major peak of pro-	ein. The peroxisomes, revealed by their catalase content, 
were at a density of 1.23 g/ml, to the right of the mi-
tochondria in Fig. 4. The peroxisomes, which in normal 
organize only about 2.5% of the total liver protein, 
constituted part of the shoulder of the protein distribution, 
but did not form a noticeable bump. The soluble 
catalase at the left end of the distribution is believed to 
have been released from peroxisomes broken during ho-
genization (20, 23). Similar amounts of soluble cata-
lag were present in the homogenates of control and 
drug-treated rats.
The distribution of palmitoyl-CoA oxidizing activity 
in the gradient from the control rats was similar to that of catalase, regardless of which assay was used, indicating that the activity measured was due to peroxisomes. The shape of the palmitoyl-CoA oxidation distributions from the clofibrate-treated rats was also peroxisomal, but the absolute activities were about 3 times greater than in the controls. This demonstrates that the increased activities measured in the homogenates were due to the peroxi-
smal β-oxidation system.

Effects of bezafibrate on male rats

Biochemical results. Bezafibrate was administered to 
male rats by stomach tube once daily for a week at a 
dose of 25 mg/kg, which has been demonstrated to be 
an effective hypolipidemic dose (19). As shown in Table 
1, this bezafibrate treatment lowered plasma triglyceride 
and cholesterol levels significantly, in agreement with the 
results of Stegmeier et al. (19).
The drug caused an 11% increase in liver weight 
(Table 1). This is the smallest increase that we have 
observed to date in our experiments with hypolipidemic 
compounds, and is much less than the 43–146% 
increases reported in the literature for six other drugs 
(7–14).
The bezafibrate treatment had no effect on the hepatic 
protein concentration or on the activities of catalase and 
cytochrome oxidase.
The capacity of the liver homogenates of the bezaf-
brate-treated rats to oxidize palmitoyl-CoA was 3.3- to 
3.5-fold greater than the controls (Table 1).

Cell fractionation results. As illustrated in Fig. 5, the 
fractionation of male rat livers gave results similar to 
those obtained with females (Fig. 4). The peroxisomal 
β-oxidation system is clearly seen to be elevated by oral 
administration of bezafibrate (Fig. 5B). In addition, we 
measured the activity of the mitochondrial β-oxidation 
system, using an assay procedure in which both peroxi-
somes and mitochondria are active (Fig. 5A). The mi-
tochondrial activity appeared to be unaffected, or perhaps 
increased slightly.

Changes in mitochondrial and peroxisomal β-oxidation. These changes were quantitated in two ways. First, we computed the mean ratio of β-oxidation/cytochrome oxidase in the two peak mitochondrial fractions, and the mean ratio of β-oxidation/catalase in the two peak peroxisomal fractions; we used these values to estimate the total mitochondrial and peroxisomal activities per g of liver. As shown in Table 2, mitochondrial β-oxidation 
apparently increased 23%, while peroxisomal β-oxidation 
increased 321%.

Second, we computed the specific activity of β-oxi-
dation throughout the two gradients. As shown in Fig. 
6, bezafibrate increased the specific activity in the per-
oxosomal region about 4-fold, but had little or no effect 
in the mitochondrial region of the gradient. Because the 
recoveries on the gradients for the β-oxidation assays 
were low, we cannot rigorously exclude the possibility 
that there was a larger change in mitochondrial β-oxi-
dation that we failed to detect for technical reasons. 
However, we found no evidence for such a change.

Morphological results. Visually, there was no notice-
able effect of bezafibrate on the number of peroxisomes. 
Morphometric analysis (Fig. 7) demonstrated that 
bezafibrate caused the number of peroxisomes and the total 
p eroxisome volume to increase 40% and 60%, respectively 
(Table 3). The size distribution of the peroxisome pop-
ulation was not appreciably affected. These changes are
Fig. 3. Peroxisomes in livers of (A) female and (B) male rats. Left: controls. Right: clofibrate-treated. The larger, irregularly shaped, stained structures are red blood cells in sinusoids; the clear round areas are nuclei. The magnifications are the same; scale bar, 10 μm. These light micrographs are typical of a much larger number that were examined.
palmitoyl-CoA oxidation

60
40
20
0
40
20
0

NAD Assay

Cytochrome oxidase (mitochondria)

NADH

Liver Activities

Palmitoyl-CoA Oxidation

A. Both organelles active
B. Mainly peroxi-
osomes active

C. Cytochrome oxidase (mitochondria)

D. Catalase

Peroxisomes

E. Protein

F. Esterase

Catalase

Palmitoyl-CoA Oxidation

Fig. 4. Fractionation of livers of normal and of clofibrate-treated female rats. Postnuclear supernatants were sedimented into linear sucrose density gradients in order to separate the various organelles, partly on the basis of size and partly on the basis of density; see reference 20 for details. The distributions of the activities from the control rats (stippled areas) are each normalized to the same surface area of 1.0 as described by Leighton et al. (23). The areas under the distributions from the clofibrate-treated rats (white areas) reflect the abundance of these components relative to the controls. Palmitoyl-CoA oxidation assays as in Fig. 1. The starting material was the postnuclear supernatant from 1 g of liver, specifically 0.33 g from each of the three rats in a group. The recoveries of the marker enzymes varied between 92 and 105%. The recoveries of the palmitoyl-CoA oxidation activities were lower, varying between 56 and 76%.

small compared to the 3- to 10-fold increases in peroxisome volume observed with other drugs (14, 16, 30, 31). No change occurred in the volume fraction of mitochondria (not illustrated).

The results presented demonstrate that certain hypolipidemic drugs are capable of specifically elevating the activity of the peroxisomal enzyme system catalyzing fatty acid β-oxidation, without affecting the main per-

Fig. 5. Fractionation of livers of normal and of bezafibrate-treated (25 mg/kg p.o.) male rats. Absolute enzyme activities are plotted; the ordinate values are chosen such that the surface areas of the control distributions (stippled areas) are all the same, as in Fig. 4. A., Oxidation of [U-14C]palmitoyl-CoA measured under conditions where both mitochondria and peroxisomes are active. 1 mM = 1 nmol palmitoyl-CoA oxidized/min. B., Oxidation of palmitoyl-CoA measured with the NAD reduction assay under conditions that mainly measure peroxisomal β-oxidation (as in Figs. 1, 2, and 4). 1 mM = 1 nmol NADH formed/min. Recoveries were 83–122% for the marker enzymes and 53–78% for palmitoyl-CoA oxidation.

DISCUSSION

The results presented demonstrate that certain hypolipidemic drugs are capable of specifically elevating the activity of the peroxisomal enzyme system catalyzing fatty acid β-oxidation, without affecting the main per-

TABLE 1. Effects of 25 mg/kg oral bezafibrate

<table>
<thead>
<tr>
<th>Rat Weight</th>
<th>Triglycerides</th>
<th>Cholesterol</th>
<th>Liver Weight</th>
<th>Protein</th>
<th>Catalase</th>
<th>Cytochrome Oxidase</th>
<th>Palmitoyl-CoA Oxidation</th>
</tr>
</thead>
<tbody>
<tr>
<td>(g)</td>
<td>(mg/100 ml)</td>
<td></td>
<td>% rat wt</td>
<td>mg/g liver</td>
<td></td>
<td></td>
<td>A&lt;sup&gt;+&lt;/sup&gt;</td>
</tr>
<tr>
<td>Control (n = 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>205</td>
<td>33</td>
<td>36</td>
<td>2.83</td>
<td>234</td>
<td>90.7</td>
<td>41.0</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>20</td>
<td>5</td>
<td>3</td>
<td>0.18</td>
<td>5</td>
<td>10.0</td>
<td>3.2</td>
</tr>
<tr>
<td>Bezafibrate (n = 6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>204</td>
<td>26</td>
<td>27</td>
<td>3.15</td>
<td>232</td>
<td>91.1</td>
<td>41.3</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>14</td>
<td>2</td>
<td>4</td>
<td>0.15</td>
<td>13</td>
<td>8.5</td>
<td>3.0</td>
</tr>
<tr>
<td>Percent of control</td>
<td>100</td>
<td>79</td>
<td>75</td>
<td>111</td>
<td>99</td>
<td>100</td>
<td>101</td>
</tr>
<tr>
<td>P value</td>
<td>0.02</td>
<td>0.01</td>
<td>0.01</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Male Fisher F-344 rats were fed Purina chow and water ad lib. Six experimental rats received 25 mg/kg of bezafibrate once daily by stomach tube as a 2.5 mg/ml suspension in 1% methylcellulose. Five control rats received methylcellulose only. Treatment was for 1 week.

b NAD reduction assay; optimal conditions for peroxisomal β-oxidation; mitochondria largely inactive.

c Oxidation of [U-14C]palmitoyl-CoA under conditions where both peroxisomes and mitochondria are active (22).
TABLE 2. Computation of peroxisomal and mitochondrial β-oxidation activities

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Bezafibrate</th>
<th>Unit</th>
<th>Percent of Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peroxisomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Palmitoyl-CoA oxidation/catalase in the two peak peroxisomal fractions (Fig. 5)</td>
<td>2.48</td>
<td>10.4</td>
<td>mU/U</td>
<td>419%</td>
</tr>
<tr>
<td>B. Mean catalase in the homogenates (Table 1)</td>
<td>90.7</td>
<td>91.1</td>
<td>U/g</td>
<td>100%</td>
</tr>
<tr>
<td>C. Peroxosomal β-oxidation (Product of A and B)</td>
<td>225</td>
<td>947</td>
<td>mU/g</td>
<td>421%</td>
</tr>
<tr>
<td>Mitochondria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. Palmitoyl-CoA oxidation/cytochrome oxidase in the two peak mitochondrial fractions (Fig. 5)</td>
<td>6.07</td>
<td>7.41</td>
<td>mU/U</td>
<td>122%</td>
</tr>
<tr>
<td>E. Mean cytochrome oxidase in the homogenates (Table 1)</td>
<td>41.0</td>
<td>41.3</td>
<td>U/g</td>
<td>101%</td>
</tr>
<tr>
<td>F. Mitochondrial β-oxidation (Product of D and E)</td>
<td>249</td>
<td>306</td>
<td>mU/g</td>
<td>123%</td>
</tr>
<tr>
<td>Whole liver</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G. Sum of calculated activities in peroxisomes and mitochondria (C + F)</td>
<td>474</td>
<td>1253</td>
<td>mU/U</td>
<td>264%</td>
</tr>
<tr>
<td>H. Percent in peroxisomes</td>
<td>47%</td>
<td>76%</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>I. Measured (Table 1)</td>
<td>495</td>
<td>1643</td>
<td>mU/g</td>
<td>332%</td>
</tr>
</tbody>
</table>

The accuracy and reproducibility of this type of fractionation experiment are such (20, 21, 23) that we consider the 321% increase in peroxisomal activity to be highly significant, but would not argue that the 23% increase in mitochondrial activity is significant. No statistics are available since this is a single fractionation of pooled livers.

This calculation assumes that all catalase is in peroxisomes and that the distributions of catalase and β-oxidation activity within the peroxisome population are the same.

Oxisomal enzyme, catalase, and without causing a striking proliferation of the organelle. It makes good biochemical sense that catalase is not obligatorily increased by hypolipidemic drugs, because it is not involved directly in lipid metabolism, and is present in sufficient quantity to dispose of the H₂O₂ generated by the acyl-CoA oxidase. Modification of its activity appears to be a less specific effect of the drugs. Moreover, the enzymes catalyzing the β-oxidation reactions are not major constituents of normal peroxisomes. Consequently, these enzymes can be increased manyfold without greatly increasing total peroxisomal protein.

Drug dose appears to be involved in differentiating the more specific biochemical effects from the other biochemical or morphological changes. Larger doses of bezafibrate cause increased hepatomegaly (32) as well as elevated catalase and obvious proliferation (33), but the elevation of β-oxidation was similar to that reported here (32). Thus, the dose response for β-oxidation apparently differs from the dose response for proliferation and other changes.
TABLE 3. Morphometric analysis of effects of bezafibrate on peroxisomes

<table>
<thead>
<tr>
<th>Measured values</th>
<th>Control</th>
<th>Bezafibrate</th>
<th>% of Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of electron micrographs</td>
<td>23</td>
<td>23</td>
<td>100%</td>
</tr>
<tr>
<td>Area analyzed (µm²)</td>
<td>788</td>
<td>762</td>
<td>97.3%</td>
</tr>
<tr>
<td>Profiles observed</td>
<td>184</td>
<td>264</td>
<td>142%</td>
</tr>
<tr>
<td>Total profile area (µm²)</td>
<td>29.7</td>
<td>45.9</td>
<td>155%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Computed values</th>
<th>Mean radius (µm)</th>
<th>± Standard deviation</th>
<th>± Number of peroxisomes/µm²</th>
<th>Volume fraction of peroxisomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bezafibrate</td>
<td>0.255</td>
<td>±0.060</td>
<td>0.639</td>
<td>140%</td>
</tr>
<tr>
<td>Bezafibrate</td>
<td>0.255</td>
<td>±0.060</td>
<td>0.639</td>
<td>140%</td>
</tr>
</tbody>
</table>

* Complementary data to Fig. 7A

Larger doses of clofibrate to female rats can elevate catalase and cause peroxisome proliferation, as shown by Reddy and Kumar (34). However, lower doses of clofibrate to male rats have not produced so far the dissociation of effects observed here with bezafibrate. For example, at a dose of clofibrate (0.05% in the chow) that increased liver weight 11%, palmitoyl-CoA oxidation was only 28% greater than controls.7

The reason for the sex difference in response to clofibrate is not known. Svoboda et al. (10) have shown that the increase in catalase activity depends on, and can be manipulated by changing, sex hormone levels.

The present results support and extend previous observations (1, 2, 7, 13, 31, 35) that the relative activities of the peroxisomal enzymes are not fixed, and the enzymatic composition of peroxisomes is subject to specific and delicate regulation.

These results, together with those of other workers (36-40), further substantiate the conclusion (4, 5) that the hypotriglyceridemic mechanism of action of these drugs involves peroxisomes. A total of seven hypolipidemic compounds has been found to cause increases in peroxisomal β-oxidation (1, 4, 5, 36-40).

In contrast, the mitochondrial β-oxidation system does not appear to be consistently affected by hypolipidemic drugs. We found only a small change (+23%) with bezafibrate (that may not be significant). Studies of the effect of clofibrate have given variable results: mitochondrial oxidation of palmitate has been reported to decrease (41), to increase (36), or not to change (37).

The possibility has been raised that peroxisome proliferators as a class may be carcinogenic in rats (17, 18). Whether this is of practical concern for the use of hypolipidemic drugs in humans deserves careful and cautious consideration. Svoboda and Azarnoff (17) note species differences in toxicity, rates of metabolism, etc. Dose may also be important. It is noteworthy that these peroxisome proliferators are not mutagenic in the Salmonella-microsome assay (42). Moreover, acetylsalicylic acid is a peroxisome proliferator in rats (43, 44), but has been widely used by humans without apparent carcinogenicity.

The finding that the specific elevation of peroxisomal β-oxidation is not obligatorily coupled to increased catalase, gross hepatomegaly, or striking peroxisome proliferations, has several implications for future work on hypolipidemic drugs. First, it is not justified to infer that a drug is inactive as a lipid-lowering agent if it does not cause obvious peroxisome proliferation. Species and sex differences with respect to proliferation do not necessarily imply similar differences with respect to efficacy.

Second, the results suggest that a rapid and sensitive method of screening for new hypolipidemic drugs would be to look for changes in peroxisomal β-oxidation, or in one of the specific β-oxidation enzymes. These parameters increase sufficiently that treatment of three rats for 1 week suffices to detect changes that are statistically highly significant.

Lastly, comparison of these observations of bezafibrate's biochemical effects on male rats with previous studies of clofibrate's effects on male rats (1, 2, 4, 5, 7-11, 15, 16, 31, 33, 34, 36, 37, 41) suggests that clofibrate acts less specifically. Thus the side effects of clofibrate recently noted in the W. H. O. trials (45) may be unrelated to the drug's lipid-lowering effects. If true, it implies that useful clinical results may be obtainable with new drugs of this class and that further research and testing may be warranted.

The dedicated technical assistance of A. Bushra is greatly appreciated, as is the recent help of J. Cary. We are indebted to Drs. T. S. Parker and E. H. Ahrens, Jr. for generously carrying out the triglyceride and cholesterol determinations and to Dr. P. Baudhuin for the use of the Quantimet 720. We thank Drs. C. de Duve, E. H. Ahrens, Jr., J. Hirsch, M. Müller, S. Fowler, and J. Kondrup for helpful criticism of this manuscript. This research was supported by NIH grant HL 20909 and NSF grants PCM77-11151 and 80-08713.

Manuscript received 13 April 1981 and in revised form 8 October 1981.
REFERENCES


34. Reddy, J. K., and N. S. Kumar. 1979. Stimulation of cat-
alase synthesis and increase of carnitine acetyltransferase activity in the liver of intact female rats fed clofibrate. *J. Biochem.* **85**: 847–856.


